The Efficacy of Second-line Treatment with the Combination of Fipronil and Tirelizumab in Patients with Advanced Colorectal Cancer and Its Impact on Serum CEA,CRP and IL-6 Levels
Objective:To explore the efficacy of the combination of furoquinib and tirelizumab in second-line treatment of advanced colorectal cancer patients,as well as its impact on serum levels of Carcinoembryonic antigen(CEA),C-reactive protein(CRP),and interleukin-6(IL-6).Methods:82 cases of advanced colorectal cancer from 2020.3 to 2023.03 were selected and divided into observation group and control group(41 cases).The fiirst-line treatment of patients was mainly FOLFOX regimen,and the observation group used second-line quintinib combined with furoquintinib and tirelibizumab,comparing relevant indicators.Results:The objective response rate and disease control rate in the observation group were higher than the control group,and CRP,IL-6,COX-2,CEA and CA199 were lower than the control group(P＜0.05);there was no difference between the two groups(P＞0.05).Conclusion:Furoquinitinib and tirellizumab are effective in the second-line treatment of advanced colorectal cancer,which can improve the objective response rate and disease control rate,and reduce the level of inflammatory response and tumor markers.
FuroquinotinibTerelizumabSecond line treatmentAdvanced colorectal cancer
万方数据
维普
